PE20161096A1 - INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß) - Google Patents
INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß)Info
- Publication number
- PE20161096A1 PE20161096A1 PE2016001267A PE2016001267A PE20161096A1 PE 20161096 A1 PE20161096 A1 PE 20161096A1 PE 2016001267 A PE2016001267 A PE 2016001267A PE 2016001267 A PE2016001267 A PE 2016001267A PE 20161096 A1 PE20161096 A1 PE 20161096A1
- Authority
- PE
- Peru
- Prior art keywords
- tgfß
- protein
- growth factor
- fragment
- binding
- Prior art date
Links
- 102000004887 Transforming Growth Factor beta Human genes 0.000 title abstract 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 title abstract 5
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 2
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 2
- 102000003839 Human Proteins Human genes 0.000 abstract 2
- 108090000144 Human Proteins Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 abstract 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 abstract 1
- 102000049939 Smad3 Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Abstract
Se refiere a: i) una proteina caracterizada porque comprende: a) un TGFßRII o un fragmento del mismo capaz de unirse a TGFß y b) un anticuerpo, o un fragmento de union a antigeno del mismo, que se une a la proteina humana Ligando 1 de muerte programada (PD-L1); y ii) un polipeptido caracterizado porque comprende: a) al menos un dominio variable de una cadena pesada de un anticuerpo que se une a la proteina humana PD-L1 y b) TGFßRII o un fragmento del mismo capaz de unirse a TGFß. Tambien se refiere a un metodo de produccion de dicha proteina y a un metodo de tratamiento. Dicha proteina inhibe la fosforilacion de SMAD3 en una celula o promueve el agotamiento local de TGFß en un tumor, siendo util en el tratamiento de cancer o en la inhibicion del crecimiento tumoral
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461938048P | 2014-02-10 | 2014-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20161096A1 true PE20161096A1 (es) | 2016-10-22 |
Family
ID=52988007
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020002093A PE20210168A1 (es) | 2014-02-10 | 2015-02-10 | INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß) |
| PE2016001267A PE20161096A1 (es) | 2014-02-10 | 2015-02-10 | INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß) |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020002093A PE20210168A1 (es) | 2014-02-10 | 2015-02-10 | INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß) |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9676863B2 (es) |
| EP (2) | EP3889172B1 (es) |
| JP (2) | JP6731346B2 (es) |
| KR (1) | KR102363008B1 (es) |
| CN (2) | CN106103488B (es) |
| AU (3) | AU2015213988B2 (es) |
| BR (1) | BR112016014952A2 (es) |
| CA (1) | CA2934979A1 (es) |
| CL (1) | CL2016002017A1 (es) |
| CY (1) | CY1124408T1 (es) |
| DK (1) | DK3105246T3 (es) |
| ES (1) | ES2876430T3 (es) |
| HR (1) | HRP20210977T1 (es) |
| HU (1) | HUE054873T2 (es) |
| IL (2) | IL246968B (es) |
| LT (1) | LT3105246T (es) |
| MX (2) | MX2016010067A (es) |
| NZ (1) | NZ721364A (es) |
| PE (2) | PE20210168A1 (es) |
| PH (1) | PH12016501549A1 (es) |
| PL (1) | PL3105246T3 (es) |
| PT (1) | PT3105246T (es) |
| RS (1) | RS62038B1 (es) |
| RU (2) | RU2021114500A (es) |
| SG (2) | SG10202108879SA (es) |
| SI (1) | SI3105246T1 (es) |
| WO (1) | WO2015118175A2 (es) |
Families Citing this family (135)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015027082A1 (en) | 2013-08-22 | 2015-02-26 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
| EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| US9676863B2 (en) | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| US11344620B2 (en) | 2014-09-13 | 2022-05-31 | Novartis Ag | Combination therapies |
| AU2015333687B2 (en) | 2014-10-14 | 2021-03-18 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to PD-L1 and uses thereof |
| MX2017011644A (es) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
| EP3277716B1 (en) | 2015-04-03 | 2020-06-24 | XOMA Technology Ltd. | Treatment of cancer using inhibitors of tgf-beta and pd-1 |
| PL3303394T3 (pl) | 2015-05-29 | 2020-11-16 | Agenus Inc. | Przeciwciała anty-ctla-4 i sposoby ich zastosowania |
| AU2016301380B2 (en) | 2015-08-04 | 2021-07-01 | Acceleron Pharma Inc. | Methods for treating myeloproliferative disorders |
| WO2017020291A1 (en) * | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| US11219694B2 (en) | 2015-09-24 | 2022-01-11 | The University Of North Carolina At Chapel Hill | Methods and compositions for reducing metastases |
| US11583593B2 (en) | 2016-01-14 | 2023-02-21 | Synthis Therapeutics, Inc. | Antibody-ALK5 inhibitor conjugates and their uses |
| US10894823B2 (en) | 2016-03-24 | 2021-01-19 | Gensun Biopharma Inc. | Trispecific inhibitors for cancer treatment |
| MX2018014047A (es) * | 2016-05-17 | 2019-06-20 | Genentech Inc | Firmas de genes estromales para el diagnóstico y uso en inmunoterapia. |
| CA3024508A1 (en) | 2016-05-27 | 2017-11-30 | Agenus Inc. | Anti-tim-3 antibodies and methods of use thereof |
| KR20190039200A (ko) * | 2016-08-12 | 2019-04-10 | 메르크 파텐트 게엠베하 | 암에 대한 조합 요법 |
| KR102617453B1 (ko) | 2016-09-19 | 2023-12-26 | 현대모비스 주식회사 | 보조 표지판 인식 장치 및 그 방법 |
| KR20190128618A (ko) | 2016-09-27 | 2019-11-18 | 에피센트알엑스, 인코포레이티드 | 면역조정 융합 단백질 |
| MA46529A (fr) | 2016-10-11 | 2019-08-21 | Agenus Inc | Anticorps anti-lag-3 et leurs procédés d'utilisation |
| JP6992068B2 (ja) | 2016-12-07 | 2022-02-03 | アジェナス インコーポレイテッド | 抗ｃｔｌａ－４抗体およびそれらの使用方法 |
| CA3046082A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Antibodies and methods of use thereof |
| CN109071656B (zh) | 2017-01-05 | 2021-05-18 | 璟尚生物制药公司 | 检查点调节物拮抗剂 |
| CA3048646A1 (en) * | 2017-01-07 | 2018-07-12 | Merck Patent Gmbh | Dosing regimens and dosage forms for targeted tgf-b inhibition |
| IL310711A (en) * | 2017-01-10 | 2024-04-01 | Intrexon Corp | Modulation of expression of polypeptides through a new system for changing gene expression |
| GB201700567D0 (en) | 2017-01-12 | 2017-03-01 | Genagon Therapeutics Ab | Therapeutic agents |
| BR112019014510A2 (pt) | 2017-01-13 | 2020-02-18 | Agenus Inc. | Receptores de célula t que se ligam ao ny-eso-1 e métodos de uso dos mesmos |
| AU2018228435A1 (en) | 2017-03-02 | 2019-10-03 | National Research Council Of Canada | TGF-beta-receptor ectodomain fusion molecules and uses thereof |
| RU2765997C2 (ru) * | 2017-03-30 | 2022-02-07 | Мерк Патент Гмбх | Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования |
| KR102629972B1 (ko) | 2017-04-13 | 2024-01-29 | 아게누스 인코포레이티드 | 항-cd137 항체 및 이의 사용 방법 |
| PL3618863T3 (pl) | 2017-05-01 | 2023-11-06 | Agenus Inc. | Przeciwciała anty- tigit i sposoby ich zastosowania |
| US11021527B2 (en) * | 2017-05-04 | 2021-06-01 | Acceleron Pharma Inc. | Transforming growth factor beta receptor type II fusion polypeptides |
| AU2018266103A1 (en) * | 2017-05-09 | 2019-11-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies |
| JP7264827B2 (ja) * | 2017-05-12 | 2023-04-25 | 江蘇恒瑞医薬股▲ふん▼有限公司 | ＴＧＦ－β受容体含有融合タンパク質およびそれらの医薬的用途 |
| EP3630836A1 (en) | 2017-05-31 | 2020-04-08 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| AU2018278327B2 (en) | 2017-06-01 | 2023-03-16 | Cytomx Therapeutics, Inc. | Activatable anti-pdl1 antibodies and methods of use thereof |
| SG11202001319QA (en) | 2017-09-04 | 2020-03-30 | Agenus Inc | T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof |
| US11834492B2 (en) | 2017-09-27 | 2023-12-05 | Epicentrx, Inc. | Human IL-10 receptor alpha fusion proteins |
| JP2021502066A (ja) * | 2017-11-06 | 2021-01-28 | ジェネンテック， インコーポレイテッド | がんの診断及び療法 |
| EP3720881A1 (en) | 2017-12-08 | 2020-10-14 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| CA3093468A1 (en) | 2018-03-09 | 2019-09-12 | Agenus Inc. | Anti-cd73 antibodies and methods of use thereof |
| EP3765516A2 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| WO2019175243A1 (en) | 2018-03-14 | 2019-09-19 | Merck Patent Gmbh | Compounds and uses thereof to treat tumors in a subject |
| US20210238280A1 (en) | 2018-03-14 | 2021-08-05 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| US11065317B2 (en) | 2018-04-26 | 2021-07-20 | Agenus Inc. | Heat shock protein-binding peptide compositions and methods of use thereof |
| AU2019262143A1 (en) * | 2018-05-03 | 2020-11-26 | Acceleron Pharma Inc. | Novel binders of TGFβ-superfamily ligands and uses thereof |
| CA3099527A1 (en) * | 2018-05-03 | 2019-11-07 | Acceleron Pharma Inc. | Multispecific binders of tgf.beta.-superfamily ligands and uses thereof |
| TW202014201A (zh) | 2018-05-04 | 2020-04-16 | 德商馬克專利公司 | 用於治療癌症之ＰＤ-１／ＰＤ-Ｌ１，ＴＧＦβ及ＤＮＡ-ＰＫ之組合抑制 |
| JP2021523096A (ja) * | 2018-05-15 | 2021-09-02 | メルク パテント ゲーエムベーハー | 未治療対象において癌を治療する際に使用するための標的ｔｇｆ−β阻害のための投与計画 |
| WO2019222676A1 (en) | 2018-05-17 | 2019-11-21 | Bolt Biotherapeutics, Inc. | Immunoconjugates |
| KR20210020098A (ko) * | 2018-06-13 | 2021-02-23 | 메르크 파텐트 게엠베하 | Iii기 nsclc의 치료 및 치료와 연관된 병리학적 상태의 완화 |
| WO2019242505A1 (zh) | 2018-06-17 | 2019-12-26 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用 |
| KR20210022680A (ko) * | 2018-06-22 | 2021-03-03 | 메르크 파텐트 게엠베하 | 담도암의 치료에 사용하기 위한 표적화된 TGF-β 억제를 위한 투약 레지멘 |
| EP3813880A4 (en) | 2018-06-29 | 2022-07-13 | Gensun Biopharma Inc. | ANTITUMORS IMMUNOTEST POINT REGULATOR ANTAGONISTS |
| MX2021000110A (es) * | 2018-07-02 | 2021-03-09 | Merck Patent Gmbh | Terapia de combinacion con inhibicion dirigida de factor de crecimiento transformante beta (tgf-beta) para el tratamiento de cancer de pulmon avanzado de celulas no peque?as. |
| DE202019005887U1 (de) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR-Antikörpermoleküle und Verwendungen davon |
| CA3105750A1 (en) * | 2018-07-09 | 2020-01-16 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| WO2020041607A1 (en) * | 2018-08-22 | 2020-02-27 | Merck Patent Gmbh | Treatment of triple negative breast cancer with targeted tgf-b inhibition |
| US20220242957A1 (en) | 2018-09-27 | 2022-08-04 | Marengo Therapeutics, Inc. | Csf1r/ccr2 multispecific antibodies |
| CN113272017A (zh) | 2018-11-01 | 2021-08-17 | 默克专利有限公司 | 抗tim-3抗体 |
| EP3873612A2 (en) * | 2018-11-01 | 2021-09-08 | Merck Patent GmbH | Methods of administering anti-tim-3 antibodies |
| BR112021008288A2 (pt) | 2018-11-09 | 2021-08-10 | Jiangsu Hengrui Medicine Co., Ltd. | composição farmacêutica de proteína de fusão do receptor tgf-ss e uso da mesma |
| JP2022512326A (ja) * | 2018-12-06 | 2022-02-03 | グアンドン ティーシーアールキュア バイオファーマ テクノロジー カンパニー リミテッド | 腫瘍抗原、ＴＧＦ－β、および免疫チェックポイントを標的とする組み合わせＴＣＲ－Ｔ細胞療法 |
| CN114026122A (zh) | 2019-02-21 | 2022-02-08 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| CA3130628A1 (en) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
| JP2022521937A (ja) | 2019-02-21 | 2022-04-13 | マレンゴ・セラピューティクス，インコーポレーテッド | ＮＫｐ３０に結合する抗体分子およびその使用 |
| US20220226491A1 (en) | 2019-03-15 | 2022-07-21 | Bolt Biotherapeutics, Inc. | Immunoconjugates Targeting PD-L1 |
| KR20220007118A (ko) * | 2019-06-10 | 2022-01-18 | 샨동 보안 바이오테크놀로지 컴퍼니, 리미티드 | PDL1 및 TGFβ에 대한 2기능성 융합 단백질 및 이의 용도 |
| WO2020252294A1 (en) | 2019-06-13 | 2020-12-17 | Bolt Biotherapeutics, Inc. | Aminobenzazepine compounds, immunoconjugates, and uses thereof |
| CN110218260A (zh) * | 2019-06-24 | 2019-09-10 | 王跃驹 | 植物作为宿主在表达m7842中的应用 |
| WO2020263312A1 (en) * | 2019-06-28 | 2020-12-30 | Gensun Biopharma, Inc. | ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD |
| US20210107969A1 (en) * | 2019-07-09 | 2021-04-15 | The Johns Hopkins University | Molecules, compositions and methods for treatment of cancer |
| JP7375163B2 (ja) * | 2019-08-15 | 2023-11-07 | ナントバイオ，インコーポレイテッド | Ｔｇｆ－ベータトラップ |
| WO2021037184A1 (zh) | 2019-08-30 | 2021-03-04 | 正大天晴药业集团南京顺欣制药有限公司 | 一种靶向PD-L1和TGF-β的融合蛋白及其用途 |
| CR20220076A (es) | 2019-08-30 | 2022-06-24 | Agenus Inc | Anticuerpos anti-cd96 y sus métodos de uso |
| JP2022546110A (ja) | 2019-09-03 | 2022-11-02 | ボルト バイオセラピューティクス、インコーポレーテッド | アミノキノリン化合物、免疫複合体、及びそれらの使用 |
| WO2021046347A1 (en) | 2019-09-04 | 2021-03-11 | Bolt Biotherapeutics, Inc. | Immunoconjugate synthesis method |
| CN112442132A (zh) * | 2019-09-05 | 2021-03-05 | 复旦大学 | 靶向肿瘤的重组双功能融合蛋白及其应用 |
| EP4038053A1 (en) | 2019-09-30 | 2022-08-10 | Bolt Biotherapeutics, Inc. | Amide-linked, aminobenzazepine immunoconjugates, and uses thereof |
| WO2021063352A1 (zh) * | 2019-09-30 | 2021-04-08 | 和铂医药(上海)有限责任公司 | 一种抗pd-l1抗原结合蛋白及其应用 |
| US11802145B2 (en) | 2019-10-21 | 2023-10-31 | Nanjing Leads Biolabs Co., Ltd. | Recombinant protein targeting PD-1 and TGFß |
| MX2022004875A (es) | 2019-10-25 | 2022-06-17 | Bolt Biotherapeutics Inc | Inmunoconjugados de tienoazepina, inmunoconjugados y usos de estos. |
| JP2023501971A (ja) | 2019-11-01 | 2023-01-20 | アレス トレーディング ソシエテ アノニム | 癌の治療のための、放射線療法と共に用いるＰＤ－１、ＴＧＦβ、及びＡＴＭの組み合わせ阻害 |
| EP4054633A1 (en) | 2019-11-05 | 2022-09-14 | Merck Patent GmbH | Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer |
| TW202128763A (zh) * | 2019-11-12 | 2021-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含有ＴＧＦ－β受體的融合蛋白及其醫藥用途 |
| TWI772984B (zh) * | 2019-11-27 | 2022-08-01 | 大陸商上海岸邁生物科技有限公司 | TGFβ/PD-L1雙特異性結合蛋白 |
| WO2021115456A1 (en) * | 2019-12-11 | 2021-06-17 | Wuxi Biologics (Shanghai) Co., Ltd. | BI-FUNCTIONAL ANTIBODY AGAINST PD-L1 AND TGFβ |
| EP3838260A1 (en) | 2019-12-20 | 2021-06-23 | Ares Trading S.A. | Igg:tgf rii fusion protein composition |
| CN113004414B (zh) * | 2019-12-20 | 2022-09-06 | 广东菲鹏制药股份有限公司 | 抗PD1和TGFβ的双功能抗体及其制备方法，以及含有其的药物组合物 |
| JP2023507620A (ja) | 2019-12-20 | 2023-02-24 | アレス トレーディング ソシエテ アノニム | ＩｇＧ：ＴＧＦβＲＩＩ融合タンパク質組成物 |
| CN113121699A (zh) * | 2019-12-30 | 2021-07-16 | 国典(北京)医药科技有限公司 | Pttrap1双特异性融合蛋白及其应用 |
| EP4084821A4 (en) | 2020-01-03 | 2024-04-24 | Marengo Therapeutics Inc | CD33-BINDING MULTIFUNCTIONAL MOLECULES AND THEIR USES |
| WO2021150702A1 (en) * | 2020-01-21 | 2021-07-29 | Bolt Biotherapeutics, Inc. | Anti-pd-l1 antibodies |
| CN115151308A (zh) * | 2020-01-21 | 2022-10-04 | 博尔特生物治疗药物有限公司 | 抗pd-l1抗体 |
| US20230093512A1 (en) * | 2020-02-18 | 2023-03-23 | Nanjing GenScript Biotech Co., Ltd. | Fusion proteins and uses thereof |
| TWI813951B (zh) * | 2020-02-25 | 2023-09-01 | 大陸商上海藥明生物技術有限公司 | 一種雙功能融合蛋白及其用途 |
| CN114466868A (zh) * | 2020-03-20 | 2022-05-10 | 荣昌生物制药(烟台)股份有限公司 | 一种双特异性融合蛋白及其应用 |
| WO2021209458A1 (en) | 2020-04-14 | 2021-10-21 | Ares Trading S.A. | Combination treatment of cancer |
| JP2023521465A (ja) | 2020-04-14 | 2023-05-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | ＩＣＯＳ抗体とＰＤ－Ｌ１抗体ＴＧＦ－β－受容体融合タンパク質とに基づく癌の併用治療 |
| EP4139363A1 (en) | 2020-04-24 | 2023-03-01 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| SG11202112792WA (en) | 2020-04-28 | 2021-12-30 | Univ Rockefeller | Neutralizing anti-sars-cov-2 antibodies and methods of use thereof |
| IL297782A (en) | 2020-05-01 | 2022-12-01 | Bolt Biotherapeutics Inc | Anti-dectin-2 antibodies |
| US20230293716A1 (en) | 2020-05-08 | 2023-09-21 | Bolt Biotherapeutics, Inc. | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
| US20230357793A1 (en) * | 2020-06-26 | 2023-11-09 | Sorrento Therapeutics, Inc. | Oncolytic herpes simplex viruses (hsv) expressing immunomodulatory fusion proteins |
| US20230365653A1 (en) | 2020-07-24 | 2023-11-16 | Mabwell (shanghai) Bioscience Co., Ltd. | Tgf-beta rii mutant and fusion protein thereof |
| US11028174B1 (en) | 2020-07-28 | 2021-06-08 | Lepu Biopharma Co., Ltd. | Bifunctional molecules targeting PD-L1 and TGF-β |
| EP4188950A1 (en) * | 2020-07-28 | 2023-06-07 | Lepu Biopharma Co., Ltd. | Bifunctional molecules targeting pd-l1 and tgf-beta |
| TW202214287A (zh) * | 2020-08-24 | 2022-04-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | TGF-β受體的融合蛋白與多靶點酪胺酸激酶抑制劑聯合在製備治療腫瘤藥物中的用途 |
| EP4204458A1 (en) | 2020-08-26 | 2023-07-05 | Marengo Therapeutics, Inc. | Methods of detecting trbc1 or trbc2 |
| AU2021331075A1 (en) | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| KR20230074144A (ko) | 2020-08-26 | 2023-05-26 | 마렝고 테라퓨틱스, 인크. | NKp30에 결합하는 항체 분자 및 이의 용도 |
| WO2022042715A1 (zh) * | 2020-08-31 | 2022-03-03 | 杭州九源基因工程有限公司 | 靶向PD-L1和TGFβ的双功能融合蛋白及其制备方法与应用 |
| CN117157314A (zh) * | 2020-09-16 | 2023-12-01 | 苏州逻晟生物医药有限公司 | Pd-l1抗体、融合蛋白及其用途 |
| WO2022057061A1 (en) * | 2020-09-16 | 2022-03-24 | Suzhou Neologics Bioscience Co., Ltd. | Pd-l1 antibodies, fusion proteins, and uses thereof |
| WO2022063114A1 (zh) * | 2020-09-23 | 2022-03-31 | 海正生物制药有限公司 | Tgfbr2-ecd突变体及包含其的融合蛋白与应用 |
| CN116323657B (zh) * | 2020-09-24 | 2023-12-08 | 上海齐鲁制药研究中心有限公司 | 同时靶向PD-L1和TGFβ的双功能分子及其医药用途 |
| CN114349867A (zh) * | 2020-10-14 | 2022-04-15 | 广东菲鹏制药股份有限公司 | 融合蛋白及其应用 |
| US20240050563A1 (en) | 2020-11-02 | 2024-02-15 | Ares Trading S.A. | Combination Treatment of Cancer |
| AU2021370991A1 (en) | 2020-11-02 | 2023-06-22 | Ares Trading S.A. | Combination treatment of cancer |
| CN114573701A (zh) * | 2020-12-02 | 2022-06-03 | 上海华奥泰生物药业股份有限公司 | 抗PD-L1/TGF-β双功能抗体及其用途 |
| US20220195066A1 (en) | 2020-12-11 | 2022-06-23 | Bolt Biotherapeutics, Inc. | Anti-cea immunoconjugates, and uses thereof |
| JP2023552790A (ja) | 2020-12-11 | 2023-12-19 | ボルト バイオセラピューティクス、インコーポレーテッド | 抗ｐｄ－ｌ１イムノコンジュゲート、及びそれらの使用 |
| JP2024501453A (ja) | 2020-12-11 | 2024-01-12 | ボルト バイオセラピューティクス、インコーポレーテッド | 抗ｃｅａイムノコンジュゲート、及びそれらの使用 |
| CN116917334A (zh) | 2021-02-22 | 2023-10-20 | 浙江道尔生物科技有限公司 | 一种具有抗癌活性的多结构域融合蛋白 |
| EP4301733A1 (en) | 2021-03-02 | 2024-01-10 | GlaxoSmithKline Intellectual Property Development Limited | Substituted pyridines as dnmt1 inhibitors |
| JP2024512056A (ja) | 2021-03-26 | 2024-03-18 | ボルト バイオセラピューティクス、インコーポレーテッド | ２－アミノ－４－カルボキサミド－ベンゾアゼピン免疫複合体、及びその使用 |
| JP2024511088A (ja) | 2021-03-26 | 2024-03-12 | ボルト バイオセラピューティクス、インコーポレーテッド | ２－アミノ－４－カルボキサミド－ベンゾアゼピン免疫複合体、及びその使用 |
| EP4333900A2 (en) | 2021-05-03 | 2024-03-13 | Merck Patent GmbH | Her2 targeting fc antigen binding fragment-drug conjugates |
| CN114773485A (zh) * | 2021-05-11 | 2022-07-22 | 江苏先声药业有限公司 | 抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子 |
| AU2022280341A1 (en) | 2021-05-25 | 2024-01-04 | Merck Patent Gmbh | Egfr targeting fc antigen binding fragment-drug conjugates |
| AU2022288571A1 (en) | 2021-06-07 | 2024-01-04 | Ares Trading S.A. | Combination treatment of cancer |
| WO2023027561A1 (ko) * | 2021-08-27 | 2023-03-02 | 세라노틱스(주) | B7-h3 및 tgfβ에 특이적으로 결합하는 이중 특이적 분자 및 이의 용도 |
| US11945856B2 (en) | 2022-01-28 | 2024-04-02 | 35Pharma Inc. | Activin receptor type IIB variants and uses thereof |
| CN114990129B (zh) * | 2022-05-11 | 2023-02-03 | 北京贝来生物科技有限公司 | 表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5785682A (en) | 1995-03-22 | 1998-07-28 | Abbott Laboratories | Pre-filled syringe drug delivery system |
| WO1998048024A1 (en) * | 1997-04-18 | 1998-10-29 | Biogen, Inc. | Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins |
| DK1252192T3 (da) | 2000-02-11 | 2006-11-20 | Merck Patent Gmbh | Forbedring af antistofbaserede fusionsproteiners serumhalveringstid |
| MXPA03008031A (es) | 2001-03-07 | 2003-12-04 | Merck Patent Gmbh | Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida. |
| WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| JP2005112812A (ja) * | 2003-10-09 | 2005-04-28 | Zeria Pharmaceut Co Ltd | リン酸化部位特異的抗体及びそれを用いたスクリーニング方法 |
| BRPI0417213A (pt) | 2003-12-24 | 2007-02-06 | Scios Inc | tratamento de gliomas malìgnos com inibidores de tgf-beta |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| US7795389B2 (en) | 2004-09-28 | 2010-09-14 | The Board Of Regents Of The University Of Texas System | Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins |
| HUE026039T2 (en) | 2005-07-01 | 2016-05-30 | Squibb & Sons Llc | Human monoclonal antibodies programmed for death ligand 1 (PD-L1) |
| CN101541832B (zh) * | 2006-09-07 | 2014-11-12 | 克鲁塞尔荷兰公司 | 能中和流感病毒h5n1的人结合分子及其应用 |
| WO2008157367A1 (en) | 2007-06-15 | 2008-12-24 | Genzyme Corporation | Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor |
| US20140127200A1 (en) | 2008-01-03 | 2014-05-08 | The Scripps Research Institute | Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains |
| WO2009152610A1 (en) | 2008-06-20 | 2009-12-23 | The Royal Institution For The Advancement Of Learning/Mcgill University | Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof |
| EP2310508A1 (en) | 2008-07-02 | 2011-04-20 | Emergent Product Development Seattle, LLC | Tgf-b antagonist multi-target binding proteins |
| CN114835812A (zh) * | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
| FR2944448B1 (fr) * | 2008-12-23 | 2012-01-13 | Adocia | Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes. |
| EP2408474B1 (en) | 2009-03-18 | 2019-06-26 | Armagen, Inc. | Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins |
| CA2777825A1 (en) | 2009-10-28 | 2011-05-19 | Abbott Biotherapeutics Corp. | Anti-egfr antibodies and their uses |
| HUE037159T2 (hu) | 2009-11-24 | 2018-08-28 | Medimmune Ltd | Targetált kötõdõ ágensek B7-H1 ellen |
| US20130129723A1 (en) * | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| EP2519544A1 (en) * | 2009-12-29 | 2012-11-07 | Emergent Product Development Seattle, LLC | Polypeptide heterodimers and uses thereof |
| EP2539367A2 (en) | 2010-02-23 | 2013-01-02 | F. Hoffmann-La Roche AG | Anti-angiogenesis therapy for the treatment of ovarian cancer |
| CA3083324A1 (en) | 2010-03-05 | 2011-09-09 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| MY193562A (en) * | 2011-08-01 | 2022-10-19 | Genentech Inc | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| AU2012344260B2 (en) | 2011-11-28 | 2017-09-07 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| DK2844667T3 (en) * | 2012-04-30 | 2018-07-30 | Biocon Ltd | Targeted / immunomodulatory fusion proteins and methods for their preparation |
| WO2013181452A1 (en) | 2012-05-31 | 2013-12-05 | Genentech, Inc. | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
| EP3003316B1 (en) | 2013-05-31 | 2020-07-22 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| EP3083687A2 (en) | 2013-12-17 | 2016-10-26 | F. Hoffmann-La Roche AG | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| US9676863B2 (en) | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| LT3180363T (lt) | 2014-08-15 | 2019-11-25 | Merck Patent Gmbh | Sirp-alfa imunoglobulino sulieti baltymai |
-
2015
- 2015-02-10 US US14/618,454 patent/US9676863B2/en active Active
- 2015-02-10 SG SG10202108879SA patent/SG10202108879SA/en unknown
- 2015-02-10 CN CN201580007865.3A patent/CN106103488B/zh active Active
- 2015-02-10 DK DK15717097.8T patent/DK3105246T3/da active
- 2015-02-10 AU AU2015213988A patent/AU2015213988B2/en active Active
- 2015-02-10 MX MX2016010067A patent/MX2016010067A/es unknown
- 2015-02-10 JP JP2016546949A patent/JP6731346B2/ja active Active
- 2015-02-10 RU RU2021114500A patent/RU2021114500A/ru unknown
- 2015-02-10 NZ NZ721364A patent/NZ721364A/en unknown
- 2015-02-10 RS RS20210783A patent/RS62038B1/sr unknown
- 2015-02-10 KR KR1020167024679A patent/KR102363008B1/ko active IP Right Grant
- 2015-02-10 HU HUE15717097A patent/HUE054873T2/hu unknown
- 2015-02-10 PT PT157170978T patent/PT3105246T/pt unknown
- 2015-02-10 PE PE2020002093A patent/PE20210168A1/es unknown
- 2015-02-10 PE PE2016001267A patent/PE20161096A1/es unknown
- 2015-02-10 CN CN202110830081.8A patent/CN113549159A/zh active Pending
- 2015-02-10 SI SI201531639T patent/SI3105246T1/sl unknown
- 2015-02-10 WO PCT/EP2015/052781 patent/WO2015118175A2/en active Application Filing
- 2015-02-10 CA CA2934979A patent/CA2934979A1/en active Pending
- 2015-02-10 LT LTEP15717097.8T patent/LT3105246T/lt unknown
- 2015-02-10 BR BR112016014952A patent/BR112016014952A2/pt not_active Application Discontinuation
- 2015-02-10 EP EP21165709.3A patent/EP3889172B1/en active Active
- 2015-02-10 SG SG11201606577YA patent/SG11201606577YA/en unknown
- 2015-02-10 EP EP15717097.8A patent/EP3105246B1/en active Active
- 2015-02-10 PL PL15717097T patent/PL3105246T3/pl unknown
- 2015-02-10 RU RU2016135062A patent/RU2752424C2/ru active
- 2015-02-10 ES ES15717097T patent/ES2876430T3/es active Active
-
2016
- 2016-07-27 IL IL246968A patent/IL246968B/en active IP Right Grant
- 2016-08-03 MX MX2021003685A patent/MX2021003685A/es unknown
- 2016-08-04 PH PH12016501549A patent/PH12016501549A1/en unknown
- 2016-08-10 CL CL2016002017A patent/CL2016002017A1/es unknown
-
2017
- 2017-06-08 US US15/617,876 patent/US20180002436A1/en not_active Abandoned
-
2019
- 2019-07-25 US US16/522,304 patent/US11370819B2/en active Active
- 2019-10-11 AU AU2019246876A patent/AU2019246876B2/en active Active
-
2020
- 2020-07-06 JP JP2020116566A patent/JP2020174674A/ja active Pending
-
2021
- 2021-03-16 IL IL281565A patent/IL281565B/en unknown
- 2021-06-18 HR HRP20210977TT patent/HRP20210977T1/hr unknown
- 2021-06-23 CY CY20211100564T patent/CY1124408T1/el unknown
-
2022
- 2022-01-20 AU AU2022200365A patent/AU2022200365A1/en active Pending
- 2022-06-07 US US17/834,458 patent/US20230056881A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20161096A1 (es) | INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß) | |
| CY1125260T1 (el) | Παραγοντες δεσμευσης tigit και χρησεις τους | |
| CY1122721T1 (el) | Αντισωματα που δεσμευουν αχl | |
| EA202091540A1 (ru) | Антитела к lilrb2 | |
| MX2016014189A (es) | Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antigeno 4 de linfocito t citotoxico (anti-ctla-4) para tratar el cancer de pulmon no microcitico. | |
| EA201790755A1 (ru) | Модуляция стимулирующих и нестимулирующих миелоидных клеток | |
| DK3458478T3 (da) | Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling | |
| MX2017004311A (es) | Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos. | |
| EA201790339A1 (ru) | Комбинированные препараты с антителами к cd40 | |
| MX2018003936A (es) | Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones. | |
| BR112016013896A2 (pt) | métodos de tratamento de câncer positivo para her2 usando antagonistas de ligação do eixo de pd-1 e anticorpos anti-her2 | |
| GEP20227343B (en) | Anti-lag3 antibodies and antigen-binding fragments | |
| MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
| PH12020552221A1 (en) | Anti-pd-1 antibodies and uses thereof | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| IL276303A (en) | Methods of treating cancer with ANTI-PD-1 antibodies | |
| NZ724013A (en) | Antibodies that bind egfr and erbb3 | |
| EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
| MX2017001959A (es) | Anticuerpos especificos para mmp9. | |
| EA201891527A1 (ru) | Композиции и способы обнаружения и лечения рака пищевода | |
| NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof | |
| EA201891528A1 (ru) | Композиции и способы обнаружения и лечения рака желудка | |
| EA201992315A1 (ru) | Композиции и способы для лечения рака легкого |